Onco Actu du 10 avril 2018

	1. Biologie
Blood flow is a major influence on tumour cell metastasis [ecancernews] In a paper published in Development Cell, researchers from the French National Institute of Health and Medical Research (INSERM) found that in the model of the zebrafish embryo, labelled circulating tumour cells (CTCs) could be followed throughout the vasculature.
Cancer cure hope for endangered Tasmanian devil [The Telegraph] A team at Cambridge University has now established that these facial tumours, known as DFT1 and DFT2, contain a receptor molecule, RTK, which oncologists already know how to target via human cancer drugs.
	1.1 Biologie - Gènes
Researchers discover 40 genes involved in early development of myeloma [Institute of Cancer Research] The researchers analysed the WES data from 804 people with myeloma alongside the WGS data of 765 myeloma patients. They found that 16 genes were disrupted in coding regions of DNA, and 15 in non-coding areas.
	2.4 Etiologie - Portables, ondes e-m
Conspiratorial fear mongering about cell phones and cancer, courtesy of The Nation [Respectful Insolence] In the end, all I can say is this: For people who claim to be agnostic about whether cell phone radiation causes cancer and other bad things, Hertsgaard and Dowie sure have a strange way of showing it. This was irresponsible journalism at its most irresponsible.
	3.1 Prévention - Tabac
Study: Stop-smoking drugs Chantix, Zyban pose no heart risks [STAT] The original study involved 8,000 smokers randomly assigned to daily use of Pfizer’s Chantix, GlaxoSmithKline’s Zyban, nicotine patches or dummy pills for 12 weeks. The extended study tracked about 2,400 participants for a year.
	4. Dépistage, diagnostic et pronostic
Patients aged over 60 who lose weight 'should be tested for cancer' [The Telegraph] The research by Oxford University found that losing weight is the key symptom of the disease, linked to at least 10 types of cancer. Experts called on GPs to refer patients with unexplained weight loss for urgent tests, in a bid to speed up diagnosis.
	4.10 Dép., diag. & prono. - Poumon
The importance of staging lung cancer consistently and correctly worldwide [The Cancer Letter] The new database, which informs the Eighth Edition of the TNM Classification of Lung Cancer (The IASLC added our data beginning with the Seventh Edition), consists of 94,708 eligible patients diagnosed around the world from 1999-2010.
	4.2 Dép., diag. & prono. - Génome
Consumers don’t need experts to interpret 23andMe genetic risk reports [STAT] Now that the BRCA1/BRCA2 report is available, we know that among our existing customers, several thousand will learn they are carriers of one or more of the variants we test for. Without affordable and direct access to this critical information, many would never know they are at high risk for cancer.
	4.5 Dép., diag. & prono. - Colorectal
Interactive App Improves Colorectal Cancer Screening Rates [NCI] The “interesting and innovative” aspect of the approach used in the new study is that “once patients made a choice about screening, they had the opportunity to order the test themselves,” said health care delivery researcher Caitlin Murphy, Ph.D., M.P.H., of the University of Texas Southwestern Medical Center, who was not involved in the new study.
	5. Traitements
Looking to the future of oncology [Pharmafile] The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves assesses some of the major movements and looks to the future of treatment.
	5.12.10 Immunothérapies - Fusions et acquisitions
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital' [Forbes] “We're in a journey to focus Novartis as a medicines company powered by data and digital,” chief executive Vas Narasimhan said on a conference call explaining the deal to analysts. “And already this year, we're off to a strong start to realize that goal.”
	5.12.2 Immunothérapies - CAR-T
China’s CAR-T Therapy Race [PharmExec] Up to now, a total of 13 CAR-T treatments have applied for clinical trials from CFDA, including Anhui Anke Biotechnology, Hrain Biotechnology, Galaxy Biomed, and Fuson.
	5.12.3 Immunothérapies-combinaisons
Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated [Bloomberg] Companies fear ceding a sales-expanding breakthrough to rivals, so they are pursuing the same elusive combination cancer strategy.
IDO Inhibitors Hit a Wall [In the Pipeline] One of the biggest things going in immuno-oncology is the combination of the existing agents (PD pathway drugs) with other mechanisms to potentiate their effects and move them into new areas. This trial shows that we don’t know as much about how to do that as we thought we did.
	5.12.4 Immunothérapies - Essais
Merck's Keytruda upends lung cancer market with latest survival win [FiercePharma] “If anything is certain about immuno-oncology, it is that nothing is certain,” Anderson wrote, adding that “the division of the 1L NSCLC market between manufacturers and approaches ... that tempted investors based on 2018 news flow to date was up-ended this morning.”
Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy [EndPoints] The pharma giant didn’t offer any data this morning, waiting for an upcoming conference. They’re also still evaluating the progression-free survival results.
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells [Merck] As part of a pre-specified analysis plan, OS was sequentially tested and was significantly improved in patients with a TPS of ≥50 percent, with a TPS of ≥20 percent and then in the entire study population with a TPS of ≥1 percent.
Merck's Keytruda meets main goal in pivotal lung cancer trial [Reuters] An independent data monitoring committee determined the trial, which tested Keytruda as a monotherapy to treat non-small cell lung cancer (NSCLC), extended the lives of patients significantly compared to chemotherapy.
	5.12.5 Immunothérapies - Pharma
Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies [EndPoints] The biotech started a Phase Ib/II study of CPI-1205, an EZH2 inhibitor combined with Yervoy, that they hope will highlight their potential in epigenetics, dialing down gene expression in cancer pathways to enhance immuno-oncology drugs that have become all the rage these days.
Immunomedics poaches AstraZeneca I-O executive as new research chief [FierceBiotech] Iannone brings more than 13 years of experience in clinical drug development, most recently working on I-O programs at AstraZeneca and its biologics arm MedImmune. Here, he oversaw the development of the company’s late immuno-oncology offering Imfinzi and was, most recently, SVP and head of immuno-oncology, global medicines development, at the British-headquartered Big Pharma.
	5.3.4 Traitements - AMM (FDA, EMA,...)
Clovis' Rubraca joins the 'three-horse' PARP race in recurrent ovarian cancer [FiercePharma] The approval will boost Rubraca sales in the field, but because of its competitors' head start, it's likely to remain a third-place player, Evercore ISI's Steve Breazzano said in a note after the Friday approval.
	5.4 Traitements - Economie
In a win for Roche, cost gatekeepers change tune to back Tecentriq in lung cancer [FiercePharma] National Health Service patients can use the med for up to two years and only if Roche provides the confidential discount it offered to snag the approval, according to a NICE document.
Tecentriq third time lucky after NICE nod in lung cancer [Pharmafile] Roche is no stranger to the process of negotiating with NICE, and this isn’t the first time it has had to manage this process with Tecentriq (atezolizumab).
	6. Lutte contre les cancers
Theresa May unveils war on prostate cancer[The Telegraph] The £75m plans announced by Theresa May will see thousands of men offered the chance to try new treatments far earlier, while testing new ways to diagnose the disease.
Theresa May launches £75m drive against prostate cancer [The Guardian] The new money will be channelled through the National Institute for Health Research clinical research network. “The NIHR will work closely with the NHS, life sciences industry, charities and research funders to support the recruitment of 40,000 men into research studies over the next five years,” said chief executive Dr Jonathan Sheffield.
	6.10 Politiques
China asserts firm grip on research data [Science] In a move few scientists anticipated, the Chinese government has decreed that all scientific data generated in China must be submitted to government-sanctioned data centers before appearing in publications. At the same time, the regulations, posted last week, call for open access and data sharing.
	6.3 Associations/Fondations
Manocherian: We have been unapologetic in advocating for 10% annual increases to NIH [The Cancer Letter] “Since we talk with almost everyone who determines annual NIH funding levels, we have a unique understanding of what is possible, and also the potential obstacles.”
How Jed Manocherian’s stealth campaign for NIH was outed by its own success [The Cancer Letter] An argument can be made that Jed Manocherian, a real estate investor and developer, was ratted out by his success. Over the past four years, ACT for NIH, an organization Manocherian founded, has been channeling political clout to advance NIH.
	6.4 Médico-éco
How to reduce health care costs? Experts say lots of ideas, few successes [STAT] They shared evidence of what clearly doesn’t work to reduce the cost of care, and a few ideas of what it might make sense to try. The first to be dismissed was the idea of making patients smarter shoppers.
Cancer drug choices tied to drugmaker payouts to doctors [Reuters] Compared to physicians who didn’t receive any payments from the manufacturers of those drugs, those who did were 84 percent more likely to prescribe a kidney medication from those companies, the study found. Payments from manufacturers were also associated with 31 percent greater likelihood that doctors would choose one of their drugs for chronic myeloid leukemia.